Abstract
As neutropenia due to bone marrow suppression is a common effect of many antineoplastic agents, we explored the ability of CAP to modify bone marrow suppression in vitro using ARA-C as a model drug. Previously we have shown concentrations of CAP below the therapeutic antimicrobial range stimulate human granulocyte/monocyte stem cells (CFU/GM) from normal and neutropenic bone marrow (NEJM 1984; 310:723). The effect of CAP in combination with ARA-C was examined using Ficoll-Hypaque separated, washed bone marrow cells from normal donors plated in agar over feeder layers containing peripheral blood cells. Colonies were counted from quadruplicate replicates after 14 days incubation. Therapeutic ARA-C concentrations (0.1 to 10 uM) inhibited CFU/GM in a dose dependent manner. The effect of CAP (1 ug/mL) is illustrated as the ratio of CFU/GM colonies with CAP to colonies without CAP for each ARA-C concentration.
The ratios are significantly different from unity at all ARA-C concentrations except 10 uM suggesting stimulation by CAP partially reverses suppression of CFU/GM by ARA-C. These data suggests CAP' may be useful for the treatment of neutropenia due to antineoplastic agents.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bostrom, B., Smith, K. & Ramsay, N. 886 CHLORAMPHENICOL (CAP) MODIFIES BONE MARROW SUPPRESSION FROM CYTOSINE ARABINOSIDE (ARA-C) IN VITRO. Pediatr Res 19, 258 (1985). https://doi.org/10.1203/00006450-198504000-00916
Issue Date:
DOI: https://doi.org/10.1203/00006450-198504000-00916